Escitalopram in Patients With Generalized Anxiety Disorder

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effect of escitalopram after 8 weeks of treatment in patients with Generalized Anxiety Disorder (GAD), to evaluate proportion of patients who respond to escitalopram during the treatment period, and to evaluate safety of escitalopram.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: H. Lundbeck A/S
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• The patient suffers from GAD, diagnosed according to ICD-10 (International Classification of Diseases)

• The patient meets criteria as set out in the national SPC for escitalopram

• The patient is, in the opinion of the investigator, otherwise healthy on the basis of a physical examination, medical history and vital signs

Exclusion Criteria:

• The patient has/has had an alcohol or drug abuse-related disorder, as defined in ICD-10

• The patient has contraindications to escitalopram

• The patient has a history of severe drug allergy or hypersensitivity, or known hypersensitivity to escitalopram

• The patient has a serious illness and/or serious sequelae thereof, including liver or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, infectious, neoplastic, or metabolic disturbance

• The patient is pregnant or breast-feeding

• The patient, if a woman of childbearing potential, is not using adequate contraception